Probi® Sensia is based on L. plantarum HEAL9 (HEAL9™), a unique clinically documented probiotic strain developed by Probi® and protected by patents worldwide. Probi® Sensia impacts the mental processes relating to the input and storage of information and how that information is used to guide a person’s function and behavior. Randomized controlled studies have shown […]
Lactiplantibacillus plantarum HEAL9 (HEAL9™) Read More »
Synbiotics by Probi and Clasado combines the most researched probiotic strains with the most comprehensively studied galactooligosaccharide (GOS) prebiotic available on the market. Bimuno® GOS is supported by over 110 publications, including 20+ clinical trials, while Probi Digestis® and Probi Defendum® boasts over 250 publications, including 80+ clinical trials. These synbiotic concepts represent truly scientifically
Synbiotics by Probi® and Clasado Read More »
Crescylia Children growth is based on L. plantarum WJL combined in a formulation with vitamin D, for the EU claim for normal growth and development of bone in children. It is a premium, stable (24 months at room temperature) probiotic available for distribution in many countries.
L. rhamnosus Rosell®-11 + L. helveticus Rosell®-52 Diarrhea, Antibiotic-Associated Diarrhea, H. pylori eradication therapy, Atopic Dermatitis Lactose intolerance in children and adults 2B CFU Atopic Dermatitis in children 2B CFU Antibiotic-associated diarrhea in children and in adults from 1B to 12B depending on age Adjunct to physician-supervised therapy in children and adults with Helicobacter pylori
Probi Defendum® is based on a combination of the probiotic strains Lactiplantibacillus plantarum HEAL9 (HEAL9™) and Lacticaseibacillus paracasei 8700:2 (L. paracasei 8700:2™), equally contributing to the clinically documented dose of 1 billion (1 B) CFU per day. Several studies describe immune effects after intake of Probi Defendum® with findings on endpoints such as decreased incidence
Probi Digestis® is based on the probiotic strain Lactiplantibacillus plantarum 299v (LP299V®). LP299V® has been documented within several areas, all related to health benefits in the gut. It is described in more than 200 scientific publications and has been subject to more than 70 clinical studies. Clinical results have been shown within areas reaching from
HappyBelly is a probiotic complex by SynBalance, specifically designed to support children’s gastrointestinal health.HappyBelly has been clinically tested in a randomized double blind placebo controlled clinical trial. 100 IBS-C subjects were randomly divided in two groups 50 supplemented with a daily dose of 4B/ day for 60 days + 30 days of follow-up and 50
Probi® Sensia is based on L. plantarum HEAL9 (HEAL9™), a unique clinically documented probiotic strain developed by Probi® and protected by patents worldwide. Probi® Sensia impacts the mental processes relating to the input and storage of information and how that information is used to guide a person’s function and behavior. Randomized controlled studies have shown
Diarrhea • Rotaviral diarrhea • Gastroenteritis Also available as Active Pharmaceutical Ingredient (API) Autism and ADH prevention • Oral health • Caries prevention • Inhibition of Streptococcus mutans
Lactobacillus rhamnosus – GG (ATCC 53103) Read More »
Restoration of the physiological intestinal balance. Pediatric gastroenteritis. Immunomodulatory activity in allergic patients (for asthma and allergic rhinitis). Induces a significant reduction of LDL cholesterol, as well as a significant improvement of the LDL / HDL ratio. Reduces the release of type 2 cytokines, induces an improvement in the th1 / th2 ratio. Deposited at
Lactobacillus salivarius I 1794 Read More »
Restoration of the physiological intestinal balance. Pediatric gastroenteritis. Immunomodulatory activity in allergic patients (for asthma and allergic rhinitis). Induces a significant reduction of LDL cholesterol, as well as a significant improvement of the LDL / HDL ratio. Reduces the release of type 2 cytokines, induces an improvement in the th1 / th2 ratio. Deposited at
Lactobacillus paracasei I 1688 Read More »
The probiotic strain Bifidobacterium lactis Lafti® B94 has been specifically documented in the area of gut health. It benefits from a strong body of clinical evidence, supported by in vitro and in vivo documentation of its modes of action. A converging body of clinical evidence: digestive comfort Gut transit in all population groups (infants from birth, children, adolescents, adults): Bifidobacterium animalis
Bifidobacterium lactis Lafti® B94 Read More »
L. plantarum WJL is a second precision probiotic developed by TargEDys in collaboration with the Functional Genomics Institute of Lyon, selected by its ability to optimize the amino acid absorption, by a stimulation of the somatotroic axis. The potenital of this strain is large: from children growth, elderly bones and muscle mass, sport nutrition to
Lactiplantibacillus plantarum WJL Read More »
A randomized, double-blind, placebo-controlled trial with 298 pre-school children (2-5 years old) that consumed CRL 1505® (0,1 billion CFU/day) or a placebo 5 days/week for 6 months showed that children in the probiotic group had a significantly lower number of infections during the study period. CRL 1505® intake lowered the incidence of upper respiratory tract
Lactobacillus rhamnosus CRL1505 Read More »
Lactobacillus reuteri LR 92 LR92 is the first and only probiotic strain that has clinically demonstrated to significantly reduce the incidence of infantile colic in the newborn child, when given, to the mothers, in the last months of pregnancy. By improving the health of the infant, LR 92 helps mothers to live more serenely during
Lactobacillus reuteri LR92 Read More »
Lactiplantibacillus plantarum 299v (LP299V®) is the most clinically documented L. plantarum strain in the world. LP299V® has been documented within several areas, all related to health benefits in the gut. It is described in more than 200 scientific publications and has been subject to more than 70 clinical studies. Clinical results have been shown within
Lactiplantibacillus plantarum 299v (LP299V®) (DSM 9843) Read More »
Several studies have shown that Lactiplantibacillus plantarum 6595 (Probi® Plantarum 6595) survives the passage through the GI tract, and attaches to the intestinal cells through a specific mannose-dependent binding mechanism. The bacteria can thereby exert its effects on the intestinal wall, and immune system. Lactiplantibacillus plantarum 6595 (Probi® Plantarum 6595) has also been shown to
Lactiplantibacillus plantarum 6595 (Probi® Plantarum 6595) Read More »
Several studies have shown that Lacticaseibacillus rhamnosus 6594 (Probi® Rhamnosus 6594) can survive and persist in the gastrointestinal tract in humans. The strain was even recovered in the faeces in nearly all subjects up to 15 days after administration. Lacticaseibacillus rhamnosus 6594 (Probi® Rhamnosus 6594) has been shown to support the immune system, as well
Lacticaseibacillus rhamnosus 6594 (Probi® Rhamnosus 6594) Read More »
MicrobiomeHUB is a space that brings together the companies of the microbiome industry
Brought to you by Clorofilla Scientific Publishing
This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.
Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963
© ALL RIGHTS RESERVED
